보고서 요약(국문)

시장 개요
전 세계 난포 자극 호르몬(FSH) 시장은 2022년 19억 달러 규모에 도달했으며, 2030년까지 29억 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 FSH 시장은 예측 기간(2023~2030년) 동안 연평균 5.8%의 성장률을 기록할 것으로 예상됩니다. 불임 증가, 불임 치료에 대한 인식 및 수용도 향상, 고령화 인구 증가 등이 FSH 시장 성장을 견인하는 요인입니다.
전 세계 FSH 시장은 최근 몇 년간 지속적으로 성장해 왔습니다. FSH는 여성의 생리 주기를 조절하고 난소 난포의 성장을 촉진하는 생식 호르몬으로, 불임 치료 및 호르몬 대체 요법에 널리 사용됩니다.

전 세계 난포 자극 호르몬(FSH) 시장은 재조합 FSH, 요로 FSH, 불임 치료, 보조 생식 기술 등을 포함하며, 이러한 요소들의 증가로 FSH 시장 점유율이 확대되고 있습니다. 전 세계 FSH 시장은 불임 치료 시술의 기술 발전, 불임 치료에 대한 인식 및 수용도 증가, 생식 건강에 대한 관심 증대 등의 요인으로 인해 성장하고 있습니다.

시장 동향
고령화 인구 증가가 FSH 시장 성장을 견인
전 세계 FSH 시장은 고령화 인구 증가에 힘입어 성장하고 있습니다. 나이가 들면서 개인의 가임 능력이 감소함에 따라, 특히 연령 관련 불임을 해결하기 위한 FSH 치료와 같은 불임 치료에 대한 수요가 증가하고 있습니다. 불임 치료에 대한 이해도 및 수용도 증가, 그리고 출산 연기 추세 또한 시장 성장에 기여하고 있습니다.

예를 들어, 세계보건기구(WHO)의 2022년 보고서에 따르면 2030년에는 전 세계 인구 6명 중 1명꼴로 60세 이상이 될 것으로 예상됩니다. 이 기간 동안 60세 이상 인구는 2020년 10억 명에서 14억 명으로 증가할 것으로 전망됩니다. 전반적으로 고령화 인구의 자녀 출산 욕구와 불임 치료 솔루션에 대한 수요가 전 세계 난포 자극 호르몬(FSH) 시장 성장을 견인하고 있습니다.
보조 생식 기술(ART)의 도입 증가가 전 세계 난포 자극 호르몬(FSH) 시장 성장의 주요 동인입니다.
보조 생식 기술(ART)은 임신을 돕기 위해 고안된 다양한 의료 기술을 포함합니다. 체외 수정(IVF)은 가장 잘 알려진 ART 유형 중 하나로, 실험실에서 난자와 정자를 혼합하여 수정시킨 후 생성된 배아를 자궁에 이식하는 방식입니다.

또한, 다낭성 난소 증후군(PCOS)의 유병률 증가는 불임 증가에 기여했습니다. PCOS는 여성 불임의 흔한 원인으로, 미국 질병통제예방센터(CDC)의 2022년 통계에 따르면 미국에서 가임기 여성의 약 6~12%에 영향을 미칩니다. PCOS의 지속적인 유병률 증가는 불임 치료에 대한 수요를 촉진하고, 결과적으로 예측 기간 동안 전 세계 난포 자극 호르몬(FSH) 시장의 성장을 견인할 것입니다.
그러나 불임 문제와 보조 생식 기술(ART)의 필요성으로 인한 개인의 심각한 정서적, 심리적 부담은 시장 성장을 저해할 것입니다.
불임과 ART의 사회심리적 영향은 광범위하며, 환자의 자아 정체성 및 자율성, 정신 건강, 성생활 및 부부 관계, 생식 효율, 치료 순응도, 임신 결과에 상당한 영향을 미칠 수 있습니다. 보조생식술(ART)을 받는 여성의 25%에서 65%가 임상적 스트레스, 불안, 그리고 낮은 자존감이나 죄책감과 같은 부정적인 감정을 경험합니다. 따라서 위에서 언급한 요인들은 난포자극호르몬(FSH) 시장의 성장을 제한하는 요인으로 작용합니다.
코로나19 영향 분석
코로나19 팬데믹과 전 세계 여러 국가의 봉쇄 조치로 인해 모든 산업 분야의 기업들의 재정 건전성이 영향을 받았습니다. 이에 따라 미국 식품의약국(FDA)은 코로나19 공중보건 비상사태 기간 동안 임상시험 참여자의 안전을 보장하고, 임상시험관리기준(GCP)을 준수하며, 임상시험의 무결성에 대한 위험을 최소화하는 등 스폰서와 연구자를 지원하기 위한 일반적인 고려 사항을 포함하는 지침을 발표했습니다.
러시아-우크라이나 전쟁 영향 분석
러시아와 우크라이나 간의 분쟁은 공급망 중단, 불확실성 및 불안정을 야기하여 전 세계 난포자극호르몬(FSH) 시장에 영향을 미칠 수 있습니다. FSH 제품 개발 및 임상시험에 차질이 생겨 혁신이 둔화될 수 있습니다. 시장 참여자들은 FSH 생산 다변화 및 대체 공급원을 모색할 가능성이 있습니다. 또한, 환율 변동 및 시장 역학 변화를 포함한 경제적 영향으로 인해 가격과 수요가 변동될 수 있습니다. 지역별로 차이가 있을 수 있으며, 분쟁 지역에 가까운 국가일수록 그 영향을 더 즉각적으로 느낄 수 있습니다. FSH 시장에서 잠재적 장애물을 극복하고 기회를 포착하기 위해 업계 이해관계자들은 지속적인 관찰과 유연성을 유지해야 합니다.

세분화 분석
전 세계 난포 자극 호르몬(FSH) 시장은 유형, 적용 분야, 최종 사용자 및 지역별로 세분화됩니다.
재조합 FSH 부문은 수요 증가에 힘입어 시장 점유율의 56.3%를 차지하고 있습니다.

재조합 FSH 제품은 실험실에서 생산되며 소변 유래 FSH 제품에 비해 여러 가지 장점을 가지고 있습니다. 가장 중요한 장점 중 하나는 소변 유래 FSH에서 흔히 발견되는 오염 물질이 없어 순도가 매우 높다는 것입니다. 이는 일관된 효능을 제공하고 오염 가능성을 줄여줍니다.

고날-f, 폴리스팀, 퓨레곤은 상당한 시장 점유율을 차지하는 재조합 인간 난포 자극 호르몬(rFSH) 제제의 예입니다. 이러한 브랜드는 효과적이고 높은 품질 기준을 충족하여 의료진과 환자 모두에게 선호되고 있습니다. 특히 체외 수정(IVF)과 같은 보조 생식 기술(ART) 시술에서 난소 자극을 조절하는 등 생식 치료 분야에서 신뢰받는 선택지입니다.
예를 들어, 바라트 세럼 앤 백신즈 리미티드(Bharat Serums and Vaccines Limited)는 재조합 인간 난포 자극 호르몬을 이용한 불임 치료 임상 시험을 진행하고 있습니다. 20세에서 39세 사이의 여성 약 250명이 이 임상 시험에 참여했으며, 현재 3상 시험 단계에 있고 2023년 11월에 완료될 예정입니다. 따라서 위와 같은 이유로 재조합 FSH 부문은 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.

지리적 분석
북미는 주요 기업들의 투자와 사업 확장에 힘입어 전체 시장 점유율의 약 41.4%를 차지했습니다.
북미 시장의 지배력은 확고한 입지를 구축하고 영향력 있는 기업들의 존재, 높아진 인식, 그리고 건강하지 못한 생활 습관과 식습관으로 인한 불임 증가율에 기인합니다. 또한, 의료비 상승, FSH 제품의 광범위한 사용, 그리고 산부인과 입원 환자 수 증가도 북미 시장 수요를 견인하고 있습니다.
더 나아가, 가임기 인식법(FAM)은 미국 국제개발처(USAID)에서 안전성, 피임 효과, 생식 생물학에 대한 기본적인 이해 등 특정 요건을 충족하는 현대적인 피임법으로 인정받고 있습니다.
FAM은 다양한 상황에서의 효능을 확인하기 위해 잘 설계된 연구를 통해 검증되었습니다. 또한, FAM은 의료진의 개입이 필요하지 않고 다양한 서비스 제공 방식을 통해 이용 가능하다는 장점이 있습니다. 앞서 언급한 요인들로 인해 북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
경쟁 환경
난포 자극 호르몬 시장의 주요 글로벌 업체로는 Merck Serono, Creative BioMart, Midas Pharma GmbH, GenPharm, Trumac Healthcare, Livzon, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions, Inc, 및 BIOGENIX INC.PVT.LTD가 있습니다.
보고서 구매 이유

• 유형, 적용 분야, 최종 사용자 및 지역별 글로벌 난포 자극 호르몬 시장 세분화를 시각화하고 주요 상업적 자산과 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 난포 자극 호르몬 시장 수준의 다양한 데이터 포인트가 담긴 Excel 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 난포 자극 호르몬 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Follicle Stimulating Hormone Market reached US$ 1.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.9 billion by 2030. The global follicle stimulating hormone market is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030). The increasing prevalence of infertility, growing awareness and acceptance of fertility treatments, and growing aging population are driving the growth of the follicle stimulating hormone market trends.
The global follicle stimulating hormone (FSH) market has been expanding continuously in recent years. FSH, a reproductive hormone, is essential in regulating the menstrual cycle and encouraging the growth of ovarian follicles in women. It is commonly utilized in fertility treatments and hormone replacement therapies.
The global follicle stimulating hormone market scope comprises components encompassing recombinant FSH, urinary FSH, infertility treatment, assisted reproductive technology and others, which has increased usage of follicle stimulating hormone market share. The global market for follicle stimulating hormones is expanding as a result of factors including technological advancements in fertility treatment procedures, increasing awareness and acceptance of fertility treatments, and increasing focus on reproductive health.
Market Dynamics
An Increase in Aging Population Drive the Growth of the Follicle Stimulating Hormone Market
The global FSH market is being driven by an aging population. Individuals' fertility potential reduces as they age, resulting in an increased demand for fertility treatments, especially FSH treatment, to address age-related infertility. The increased understanding and acceptability of fertility treatments, as well as the trend of postponed childbirth, have all contributed to the market's rise.
For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. Overall, the aging population's desire for parenthood and the need for fertility solutions drive the growth of the global follicle stimulating hormone market.
Growing Adoption of Assisted Reproductive Technology is the Major Driver in the Global Follicle Stimulating Hormone Market
The use of assisted reproductive technology (ART) includes a variety of medical techniques designed to aid individuals in achieving pregnancy. In vitro fertilization (IVF) is one of the most well-known types of ART, in which eggs and sperm are mixed in a laboratory setting to fertilize and then implant the resulting embryos into the uterus.
Furthermore, the rising prevalence of polycystic ovary syndrome (PCOS) has contributed to an increase in infertility. PCOS is a common cause of female infertility, affecting roughly 6% to 12% of women of reproductive age in the United States, according to the Centers for Disease Control and Prevention (CDC) 2022 statistics. The continued prevalence of PCOS will drive demand for infertility treatments, consequently propelling the global follicle stimulating hormone market over the forecast period.
Significant Emotional and Psychological Toll on Individuals Due to Fertility Challenges and the Need for Assisted Reproductive Technologies Will Hamper the Growth of the Market.
The psychosocial consequences of infertility and ART are extensive, and they can have a significant impact on patients' sense of self-identity and personal agency, mental well-being, sexual and marital relationships, reproductive efficiency, treatment compliance, and pregnancy outcomes. Between 25% and 65% of women receiving ART experience clinical stress, anxiety, and negative emotions such as low self-esteem or guilt. Hence, the above mentioned factors are limiting the follicle stimulating hormone market’s growth.
COVID-19 Impact Analysis
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
Russia-Ukraine War Impact Analysis
The conflict between Russia and Ukraine has the potential to cause supply chain interruptions, uncertainty, and instability, which could affect the worldwide follicle-stimulating hormone (FSH) market. FSH product development and clinical trials would be impacted, which would slow down innovation. Market participants might look for FSH production diversification and alternate sources.
Furthermore, pricing and demand may be impacted by the economic impact, which includes currency fluctuations and modifications to market dynamics. There may be regional variances, with nations closer to the conflict feeling the effects more immediately. In order to navigate potential obstacles and seize possibilities in the FSH market, industry stakeholders must maintain constant observation and flexibility.
Segment Analysis
The global follicle stimulating hormone market is segmented based on type, application, end user, and region.
Recombinant FSH Segment Accounts for 56.3% of the Market Share Owing to Rising Demand for it.
Recombinant FSH products are produced in the laboratory and have various advantages over urinary-derived FSH products. One significant advantage is their superior purity, as they are free of contaminants commonly present in urinary-derived FSH. This provides consistent potency and reduces the possibility of contamination.
Gonal-f, Follistim, and Puregon are examples of rFSH medicines that have a sizable market share. Because of their effectiveness and high-quality standards, these brands have gained favor among healthcare providers and patients. They are trusted choices in reproductive treatments, including regulated ovarian stimulation in ART procedures such as IVF.
For instance, Bharat Serums and Vaccines Limited is conducting a clinical trial using Recombinant Human Follicle Stimulating Hormone for treating infertility. About 250 women in the age group of 20 to 39 years have participated in this trial and currently, it is in phase 3 trial and the estimated completion of the trial is in November 2023. Therefore, owing to the above reasons, the recombinant FSH segment is expected to drive the market growth over the forecast period.
Geographical Analysis
North America Accounted for Approximately 41.4% of the Market Share Owing to the Investment by the Major Players’ Presence in this Region
North America's market dominance has been facilitated by the presence of established and influential companies, increased awareness and an increase in the rate of infertility growth which is related to unhealthy lifestyles and diets. Also, the rising healthcare costs and the widespread use of FSH products, along with an increase in inpatient visits to gynecologists are driving the market demand in North America.
Furthermore, Fertility Awareness Methods (FAMs), for example, are recognized by the United States Agency for International Development (USAID) as modern contraceptives that meet specified requirements, such as safety, effectiveness in preventing conception, and a basic grasp of reproductive biology.
FAMs have been evaluated in well-designed studies to determine their efficacy under a variety of situations. FAMs also have the advantage of not requiring clinical involvement and can be delivered through a variety of service delivery methods. As a result of the aforementioned factors, the North American region is expected to hold the biggest market share throughout the projection period.
Competitive Landscape
The major global players in the follicle stimulating hormone market include Merck Serono, Creative BioMart, Midas Pharma GmbH, GenPharm, Trumac Healthcare, Livzon, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions, Inc, and BIOGENIX INC.PVT.LTD.
Why Purchase the Report?
• To visualize the global follicle stimulating hormone market segmentation based on type, application, end user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Follicle stimulating hormone market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global follicle stimulating hormone market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. An Increase in Aging Population
4.1.1.2. Growing Adoption of Assisted Reproductive Technology
4.1.2. Restraints
4.1.2.1. Emotional and Psychological Toll on Individuals due to Fertility Challenges
4.1.3. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Recombinant FSH*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Urinary FSH
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Infertility Treatment*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Assisted Reproductive Technology (ART)
8.4. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Infertility Center*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospitals
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Spain
10.3.6.5. Italy
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
Australia
10.5.6.4. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Merck Serono*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Creative BioMart
12.3. Midas Pharma GmbH
12.4. GenPharm
12.5. Trumac Healthcare
12.6. Livzon
12.7. Shanghai Techwell Biopharmaceutical Co., Ltd.
12.8. Merck Sharp & Dohme Corp
12.9. Lee Biosolutions,Inc
12.10. BIOGENIX INC.PVT.LTD.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Merck Serono, 4.	Key Developments, Creative BioMart, Midas Pharma GmbH, GenPharm, Trumac Healthcare, Livzon, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions,Inc, BIOGENIX INC.PVT.LTD.

표 목록 (Tables)

List of Tables

Table 1 Global Follicle Stimulating Hormone Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Follicle Stimulating Hormone Market Value, By Application, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Follicle Stimulating Hormone Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Follicle Stimulating Hormone Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Follicle Stimulating Hormone Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Follicle Stimulating Hormone Market Value, By Type, 2021-2030 (US$ Billion)

Table 7 Global Follicle Stimulating Hormone Market Value, By Application, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Follicle Stimulating Hormone Market Value, By Application, 2021-2030 (US$ Billion)

Table 9 Global Follicle Stimulating Hormone Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Follicle Stimulating Hormone Market Value, By End User, 2021-2030 (US$ Billion)

Table 11 Global Follicle Stimulating Hormone Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Follicle Stimulating Hormone Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Follicle Stimulating Hormone Market Value, By Type, 2021-2030 (US$ Billion)

Table 14 North America Follicle Stimulating Hormone Market Value, By Application, 2021-2030 (US$ Billion)

Table 15 North America Follicle Stimulating Hormone Market Value, By End User, 2021-2030 (US$ Billion)

Table 16 North America Follicle Stimulating Hormone Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Follicle Stimulating Hormone Market Value, By Type, 2021-2030 (US$ Billion)

Table 18 South America Follicle Stimulating Hormone Market Value, By Application, 2021-2030 (US$ Billion)

Table 19 South America Follicle Stimulating Hormone Market Value, By End User, 2021-2030 (US$ Billion)

Table 20 South America Follicle Stimulating Hormone Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Follicle Stimulating Hormone Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 Europe Follicle Stimulating Hormone Market Value, By Application, 2021-2030 (US$ Billion)

Table 23 Europe Follicle Stimulating Hormone Market Value, By End User, 2021-2030 (US$ Billion)

Table 24 Europe Follicle Stimulating Hormone Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Follicle Stimulating Hormone Market Value, By Type, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Follicle Stimulating Hormone Market Value, By Application, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Follicle Stimulating Hormone Market Value, By End User, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Follicle Stimulating Hormone Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Follicle Stimulating Hormone Market Value, By Type, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Follicle Stimulating Hormone Market Value, By Application, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Follicle Stimulating Hormone Market Value, By End User, 2021-2030 (US$ Billion)

Table 32 Merck Serono: Overview

Table 33 Merck Serono: Product Portfolio

Table 34 Merck Serono: Key Developments

Table 35 Creative BioMart: Overview

Table 36 Creative BioMart: Product Portfolio

Table 37 Creative BioMart: Key Developments

Table 38 Midas Pharma GmbH: Overview

Table 39 Midas Pharma GmbH: Product Portfolio

Table 40 Midas Pharma GmbH: Key Developments

Table 41 GenPharm: Overview

Table 42 GenPharm: Product Portfolio

Table 43 GenPharm: Key Developments

Table 44 Trumac Healthcare: Overview

Table 45 Trumac Healthcare: Product Portfolio

Table 46 Trumac Healthcare: Key Developments

Table 47 Livzon: Overview

Table 48 Livzon: Product Portfolio

Table 49 Livzon: Key Developments

Table 50 Shanghai Techwell Biopharmaceutical Co., Ltd. : Overview

Table 51 Shanghai Techwell Biopharmaceutical Co., Ltd. : Product Portfolio

Table 52 Shanghai Techwell Biopharmaceutical Co., Ltd. : Key Developments

Table 53 Merck Sharp & Dohme Corp: Overview

Table 54 Merck Sharp & Dohme Corp: Product Portfolio

Table 55 Merck Sharp & Dohme Corp: Key Developments

Table 56 Lee Biosolutions,Inc: Overview

Table 57 Lee Biosolutions,Inc: Product Portfolio

Table 58 Lee Biosolutions,Inc: Key Developments

Table 59 BIOGENIX INC.PVT.LTD.: Overview

Table 60 BIOGENIX INC.PVT.LTD.: Product Portfolio

Table 61 BIOGENIX INC.PVT.LTD.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Follicle Stimulating Hormone Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Follicle Stimulating Hormone Market Share, By Application, 2022 & 2030 (%)

Figure 4 Global Follicle Stimulating Hormone Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Follicle Stimulating Hormone Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Follicle Stimulating Hormone Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 7 Recombinant FSH Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 8 Urinary FSH Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 9 Global Follicle Stimulating Hormone Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 10 Infertility Treatment Application in Global Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 11 Assisted Reproductive Technology (ART) Application in Global Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 12 Others Application in Global Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 13 Global Follicle Stimulating Hormone Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 14 Infertility Center End User in Global Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 15 Hospitals End User in Global Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 16 Others End User in Global Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 17 Global Follicle Stimulating Hormone Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 18 North America Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 19 Asia-Pacific Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 20 Europe Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 21 South America Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 22 Middle East and Africa Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 23 North America Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 24 North America Follicle Stimulating Hormone Market Share, By Type, 2022 & 2030 (%)

Figure 25 North America Follicle Stimulating Hormone Market Share, By Application, 2022 & 2030 (%)

Figure 26 North America Follicle Stimulating Hormone Market Share, By End User, 2022 & 2030 (%)

Figure 27 North America Follicle Stimulating Hormone Market Share, By Country, 2022 & 2030 (%)

Figure 28 South America Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 29 South America Follicle Stimulating Hormone Market Share, By Type, 2022 & 2030 (%)

Figure 30 South America Follicle Stimulating Hormone Market Share, By Application, 2022 & 2030 (%)

Figure 31 South America Follicle Stimulating Hormone Market Share, By End User, 2022 & 2030 (%)

Figure 32 South America Follicle Stimulating Hormone Market Share, By Country, 2022 & 2030 (%)

Figure 33 Europe Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 34 Europe Follicle Stimulating Hormone Market Share, By Type, 2022 & 2030 (%)

Figure 35 Europe Follicle Stimulating Hormone Market Share, By Application, 2022 & 2030 (%)

Figure 36 Europe Follicle Stimulating Hormone Market Share, By End User, 2022 & 2030 (%)

Figure 37 Europe Follicle Stimulating Hormone Market Share, By Country, 2022 & 2030 (%)

Figure 38 Asia-Pacific Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 39 Asia-Pacific Follicle Stimulating Hormone Market Share, By Type, 2022 & 2030 (%)

Figure 40 Asia-Pacific Follicle Stimulating Hormone Market Share, By Application, 2022 & 2030 (%)

Figure 41 Asia-Pacific Follicle Stimulating Hormone Market Share, By End User, 2022 & 2030 (%)

Figure 42 Asia-Pacific Follicle Stimulating Hormone Market Share, By Country, 2022 & 2030 (%)

Figure 43 Middle East & Africa Follicle Stimulating Hormone Market Value, 2021-2030 (US$ Billion)

Figure 44 Middle East & Africa Follicle Stimulating Hormone Market Share, By Type, 2022 & 2030 (%)

Figure 45 Middle East & Africa Follicle Stimulating Hormone Market Share, By Application, 2022 & 2030 (%)

Figure 46 Middle East & Africa Follicle Stimulating Hormone Market Share, By End User, 2022 & 2030 (%)

Figure 47 Merck Serono: Financials

Figure 48 Creative BioMart: Financials

Figure 49 Midas Pharma GmbH: Financials

Figure 50 GenPharm: Financials

Figure 51 Trumac Healthcare: Financials

Figure 52 Livzon: Financials

Figure 53 Shanghai Techwell Biopharmaceutical Co., Ltd. : Financials

Figure 54 Merck Sharp & Dohme Corp: Financials

Figure 55 Lee Biosolutions,Inc: Financials

Figure 56 BIOGENIX INC.PVT.LTD.: Financials

세계 난포 자극 호르몬 시장 – 2023-2030

Global Follicle Stimulating Hormone Market - 2023-2030